SummaryRMgm-632
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21790945 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | E. Deligianni; I. Siden-Kiamos |
Name Group/Department | Institute of Molecular Biology and Biotechnology |
Name Institute | FORTH |
City | Heraklion |
Country | Greece |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-632 |
Principal name | actII (-) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Production of normal numbers of male and female gametocytes. Male gametocytes show a strong reduction in gamete formation (exflagellation) |
Fertilization and ookinete | Production of normal numbers of male and female gametocytes. Male gametocytes show a strong reduction in gamete formation (exflagellation) and ookinete formation was reduced ~50 fold compared to wild type. |
Oocyst | Male gametocytes show a strong reduction in gamete formation (exflagellation) and ookinete formation is reduced ~50 fold compared to wild type. No oocysts are formed in Anopheles gambiae mosquitoes. |
Sporozoite | Ookinete formation is reduced ~50 fold compared to wild type and no oocysts are formed in Anopheles gambiae mosquitoes. |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Analyses of blood stages of a mutant expressing GFP under the control of the 1.2kb promoter region of actin II (RMgm-634) indicate 'upregulated expression the the male gametocytes' and low or absent actin II expression in asexual blood stages and female gametocytes. Analyses of blood stages of a mutant expressing a GFP-tagged form of Actin II (RMgm-633) indicate exclusive expression the the male gametocytes (male gamete). Evidence is presented that the protein is located exclusively in the cytoplasm with no apparent accumulation to subcellular structures. Eight min after male activation the protein was observed in a narrow rim of cytoplasm surrounding the nucleus. In contrast Actin I was detected in both the cytoplasm and nuclei of non-activated gametocytes as shown by staining with an anti Actin I antibody. No specific localization of GFP-Actin II to the axonemes could be detected in double stainings of activated gametocytes/male gametes with an anti-tubulin antibody. The function of the mutant was restored by complementing the actII(-) line with the wild type actin II gene under control of it own promoter and regulated by the 3’UTR of the P. berghei dhfr-ts gene. The complementary actin II gene was inserted into the small subunit ribosomal rna gene (c-type unit) by single cross-over integration. In this complemented parasite line actIIC, actin II transcripts were readily detectable by RT-PCR. The complemented parasites were tested for exflagellation and ookinete conversion, which revealed partial complementation. Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1030100 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1412500 | ||||||||||||||||||||||||
Gene product | actin II | ||||||||||||||||||||||||
Gene product: Alternative name | actin2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI, BamHI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | Of the 1263bp actin II open reading frame, nucleotides 404 - 727 were disrupted by the genetic modification. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |